Description
Letrovista Coated Tablets 2.5 mg. № 30
Composition
Letrozole – 2.5 mg per tablet, lactose monohydrate, maize starch, povidone, sodium starch glycolate, magnesium stearate, hypromellose, macrogol 6000, titanium dioxide (E171).
Mechanism of Action
Letrovista tablets contain Letrozole, which is an aromatase inhibitor. It works by reducing estrogen levels in postmenopausal women, thereby inhibiting the growth of hormone-sensitive tumors.
Pharmacological Properties
Letrovista tablets exhibit potent aromatase inhibitory effects, leading to decreased estrogen production in the body. This action helps in preventing the growth and proliferation of hormone receptor-positive breast cancer cells.
Indications for Use
Letrovista tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.
Contraindications
Do not use Letrovista tablets if you are pregnant, breastfeeding, or allergic to letrozole or any other ingredients in the product.
Side Effects
Common side effects of Letrovista tablets may include hot flashes, fatigue, and joint pain. If you experience any severe or persistent side effects, contact your healthcare provider.
Usage Instructions
The recommended dosage of Letrovista coated tablets is 2.5 mg once daily, with or without food, or as directed by a healthcare professional. Swallow the tablet whole with a glass of water. Do not crush or chew the tablet.
Benefits Compared to Analogues
Letrovista has shown superior efficacy over tamoxifen in terms of disease-free survival and overall survival in postmenopausal women with early breast cancer. Its established tolerability profile and effectiveness make it a preferred adjuvant treatment option.
Suitable Patient Groups
Letrovista tablets are suitable for postmenopausal women with hormone receptor-positive early breast cancer. Consult a healthcare provider for individualized treatment recommendations for children, elderly patients, or other specific patient groups.
Storage and Shelf Life
Store Letrovista tablets in a cool, dry place away from moisture and sunlight. Check the expiration date on the packaging and do not use the product after the specified shelf life.
Packaging Description
Letrovista tablets are available in a package containing 30 coated tablets. The packaging is designed to protect the tablets from external factors that may affect their quality and efficacy.
Scientific Evidence
Letrovista (letrozole) has been extensively studied in clinical trials for its efficacy in the treatment of hormone receptor-positive breast cancer. Research has shown that letrozole is a potent aromatase inhibitor, effectively reducing estrogen levels in postmenopausal women, thereby inhibiting the growth of hormone-sensitive tumors.
Clinical trials have demonstrated the superiority of letrozole over tamoxifen in terms of disease-free survival and overall survival in postmenopausal women with early breast cancer. Letrozole has become a standard adjuvant treatment option due to its proven efficacy and tolerability profile.
Additional Information
It is important to notify your healthcare provider about any other medications you are taking before starting Letrovista tablets to prevent potential drug interactions. Always consult your doctor for personalized medical advice and follow-up while taking Letrovista tablets to ensure optimal treatment outcomes and monitoring of any potential side effects.
